BioLineRx (BLRX) Retained Earnings (2021 - 2025)

BioLineRx has reported Retained Earnings over the past 5 years, most recently at -$401.0 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$401.0 million for Q4 2025, down 28219.35% from a year ago — trailing twelve months through Dec 2025 was -$401.0 million (down 28219.35% YoY), and the annual figure for FY2025 was -$401.0 million, down 28219.35%.
  • Retained Earnings for Q4 2025 was -$401.0 million at BioLineRx, down from -$1.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for BLRX hit a ceiling of -$1.4 million in Q4 2023 and a floor of -$401.0 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$305.0 million (2021), compared with a mean of -$207.8 million.
  • Biggest five-year swings in Retained Earnings: surged 99.57% in 2023 and later crashed 28219.35% in 2025.
  • BioLineRx's Retained Earnings stood at -$305.0 million in 2021, then dropped by 8.18% to -$330.0 million in 2022, then surged by 99.57% to -$1.4 million in 2023, then changed by 0.0% to -$1.4 million in 2024, then crashed by 28219.35% to -$401.0 million in 2025.
  • The last three reported values for Retained Earnings were -$401.0 million (Q4 2025), -$1.4 million (Q4 2024), and -$1.4 million (Q4 2023) per Business Quant data.